{"product_id":"moffitt-cancer-center-20th-annual-clinical-breakthroughs-and-challenges-in-hematologic-malignancies-2025","title":"Moffitt Cancer Center 20th Annual Clinical Breakthroughs and Challenges in Hematologic Malignancies 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: hematologists, oncologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n  \u003cli\u003eWhat You Will Learn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eAttendees were able to:\u003c\/h3\u003e\n\u003cp\u003eEvaluate the latest clinical data regarding CAR T-cell therapy and bispecific antibodies, specifically their sequencing and toxicity management in lymphoma and myeloma.\u003c\/p\u003e\n\u003cp\u003eDiscuss the role of Measurable Residual Disease (MRD) testing in guiding treatment decisions for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).\u003c\/p\u003e\n\u003cp\u003eIdentify new therapeutic targets and agents for Relapsed\/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma.\u003c\/p\u003e\n\u003cp\u003eAnalyze the “Hot Topics” in blood cancers, including the management of clonal hematopoiesis and its risk implications for older adults.\u003c\/p\u003e\n\u003cp\u003eDebate controversial management strategies, such as the use of hypomethylating agents prior to transplant in high-risk MDS, through interactive pro\/con sessions.\u003c\/p\u003e\n\u003cp\u003eImplement best practices for managing complications of novel immunotherapies, including Cytokine Release Syndrome (CRS) and neurotoxicity (ICANS).\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eEvent Details\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eDate: January 25, 2025\u003c\/p\u003e\n\u003cp\u003eLocation: Florida (Historically held at venues like The Don CeSar in St. Pete Beach or Disney’s Grand Floridian in Orlando; the 21st Annual is confirmed for St. Pete Beach).\u003c\/p\u003e\n\u003cp\u003eOrganizer: Moffitt Cancer Center\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eWho Should Attend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eThe conference is tailored for the interdisciplinary hematology-oncology team:\u003c\/h3\u003e\n\u003cp\u003eHematologists and Medical Oncologists\u003c\/p\u003e\n\u003cp\u003eOncology Nurses and Nurse Practitioners\u003c\/p\u003e\n\u003cp\u003ePhysician Assistants\u003c\/p\u003e\n\u003cp\u003ePharmacists specializing in oncology\/hematology\u003c\/p\u003e\n\u003cp\u003eResearch Scientists and Fellows\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eWhy Attend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCutting-Edge Science: Moffitt Cancer Center is a leader in cellular therapy (CAR T), and this conference provides direct access to the faculty driving these innovations.\u003c\/p\u003e\n\u003cp\u003eDebate Format: Unlike standard lecture series, this event features “Interactive Debates” (e.g., Transplant vs. CAR T in Myeloma), which help clinicians understand the nuance behind conflicting guidelines.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eState-of-the-Art – Understanding Precursor States – CHIP and CCUS\u003c\/p\u003e\n\u003cp\u003e2025 Updates on Treating Anemia in LR-MDS\u003c\/p\u003e\n\u003cp\u003eDebate – Should MRD Status Be Used to Alter Treatment Decisions in High-Risk MDS \u0026amp; AML – Yes\u003c\/p\u003e\n\u003cp\u003eDebate – Should MRD Status Be Used to Alter Treatment Decisions in High-Risk MDS \u0026amp; AML – No\u003c\/p\u003e\n\u003cp\u003eBeyond CAR-T – Management of Post-BCMA CAR-T Relapse in RRMM\u003c\/p\u003e\n\u003cp\u003eHow I Treat High-Risk Multiple Myeloma – Interactive Case Discussion\u003c\/p\u003e\n\u003cp\u003eAQUILA Trial – Daratumumab vs. Active Monitoring in SMM – Perspectives for Practice\u003c\/p\u003e\n\u003cp\u003eSummary of Data for Transplant-Ineligible NDMM – Proposed SoC Approach\u003c\/p\u003e\n\u003cp\u003eLR-MDS Updates + Panel Discussion – Focus on Ph3 IMerge Trial\u003c\/p\u003e\n\u003cp\u003eGolcadomide + R-CHOP in High-Risk, Untreated Aggressive B-cell Lymphoma – Panel Discussion on Future of 1L Therapy in DLBCL\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405803573444,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Moffitt-Cancer-Center-20th-Annual-Clinical-Breakthroughs-and-Challenges-in-Hematologic-Malignancies-2025.jpg?v=1784216414","url":"https:\/\/medicalcoursespro.com\/products\/moffitt-cancer-center-20th-annual-clinical-breakthroughs-and-challenges-in-hematologic-malignancies-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}